Blockchain Registration Transaction Record

Creative Biolabs Expands Complement Assay Services to Accelerate Therapeutics Development

Creative Biolabs expands complement assay services with C3b deposition, hemolytic inhibition, and component activity tests to accelerate complement therapeutics development.

This expansion matters because it provides researchers with essential tools to evaluate complement-targeted therapies more efficiently. By offering robust assays like C3b deposition and hemolytic inhibition, Creative Biolabs helps overcome common hurdles in drug development, potentially speeding up the delivery of new treatments for diseases involving the complement system, such as autoimmune disorders and inflammatory conditions. Reliable assay services can reduce costs and time in preclinical stages, enabling more candidates to reach clinical trials and ultimately benefit patients.